On June 9 – 11, 2025, FCF hosted its sixth Fibrolamellar Scientific Summit. The goal of this meeting was to bring together the fibrolamellar research community to share knowledge and to collaborate in the search for a cure.

The opening session of the conference featured a panel discussion highlighting the latest advancements in targeted immunotherapy for FLC. Titled Oncogene-Targeted Immune Therapy in FLC, this panel featured two clinician-researchers who are pioneering clinical trials of therapeutic vaccines aimed at FLC’s fusion protein, and a patient currently enrolled in one of those trials.

Specifically, the panelists included:

• Juliane Walz, MD – University of Tübingen,
• Mark Yarchoan, MD – Johns Hopkins University,
• Molly Hones – FLC patient and clinical trial participant, and
• Mark Furth, PhD – Chief Science Officer, FCF (as moderator).

You can watch the full discussion in the video below: